Ian John Massey
Director/Board Member at ImStar Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel J. Wattier | M | - |
ImStar Therapeutics, Inc.
 ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada.
QLT, Inc.
 QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 12 years |
| Jean-Pierre Julien | M | - |
ImStar Therapeutics, Inc.
ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | 12 years |
| H. Christian Fibiger | M | 80 |
ImStar Therapeutics, Inc.
ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada.
GABA Therapeutics, Inc.
 GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | - |
| Mario David Saltarelli | M | 63 |
GABA Therapeutics, Inc.
GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | 2 years |
| Richard Gregory Farrell | M | - |
GABA Therapeutics, Inc.
GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | - |
| Julia G. Levy | M | 89 |
ImStar Therapeutics, Inc.
ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | - |
| Jeffrey Charpentier | M | - |
ImStar Therapeutics, Inc.
ImStar Therapeutics, Inc. BiotechnologyHealth Technology ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada. | 8 years |
| Kevin A. Marks | M | - |
Roche Palo Alto LLC
 Roche Palo Alto LLC Pharmaceuticals: MajorHealth Technology Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA. | 24 years |
| Florian Brand | M | 37 |
GABA Therapeutics, Inc.
GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | - |
| Matthias Luz | M | - |
GABA Therapeutics, Inc.
GABA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gaba Therapeutics, Inc. is biotechnology company. It develops its compound GRX-917 for anxiety, depression and a broad range of neurological disorders. The company is headquartered in Newport Beach, CA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Meckler | M | 57 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 4 years |
| Alan Colman | M | 75 |
University of Oxford
| 8 years |
| Jason Aryeh | M | 55 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| John Kozarich | M | 74 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| Martin M. McGlynn | M | 78 |
StemCells, Inc.
 StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | 15 years |
| John Thornton | M | 70 |
University of Oxford
| 4 years |
| Alan Osborne Trounson | M | 78 |
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | 2 years |
| Jackie Sheppard | F | 68 |
University of Oxford
| 5 years |
| Peter Jones | M | 67 |
University of Oxford
| 3 years |
| Andrew N. Rowan | M | - |
University of Oxford
| 4 years |
| Davide Giacomo Federico Benello | M | 70 |
University of Oxford
| 4 years |
| Margaret A. Wheatley | M | - |
University of Oxford
| 7 years |
| Paul Hastings | M | 64 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 4 years |
| Stephen Sabba | M | 64 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| Stephen Huhn | M | 63 |
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | 9 years |
| Geoffrey F. Cox | M | 80 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| C. Boyd Clarke | M | 74 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 9 years |
| Kathryn Falberg | F | 63 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 3 years |
| John Thomas | M | 70 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| Dori Christine Assaly | F | - |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| R. Greer | M | 65 |
StemCells, Inc.
StemCells, Inc. BiotechnologyHealth Technology StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The company is focused on developing and commercializing stem and progenitor cells as the basis for novel therapeutics and therapies; and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA. | 6 years |
| Bruce Carter | M | 80 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | 6 years |
| David Climie | M | - |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | - |
| John M. Brandow | M | - |
University of Oxford
| 4 years |
| George Adams | M | 68 |
University of Oxford
| 3 years |
| Anthony Quinn | M | 62 |
Roche Palo Alto LLC
Roche Palo Alto LLC Pharmaceuticals: MajorHealth Technology Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA. | 5 years |
| David Green | M | - |
University of Oxford
| 4 years |
| Peter J. Kalis | M | - |
University of Oxford
| 3 years |
| David Hawkes | M | 71 |
University of Oxford
| 4 years |
| Viscount Thomas Orlando Chandos | M | 69 |
University of Oxford
| 4 years |
| Peter J. Horsburgh | M | - |
University of Oxford
| 3 years |
| Viscount Nicholas Bearsted | M | 74 |
University of Oxford
| 4 years |
| Soo Sen Chan | M | 67 |
University of Oxford
| 4 years |
| Tom G. Lupton | M | 68 |
University of Oxford
| 4 years |
| Nicholas Allard | M | - |
University of Oxford
| 1 years |
| Jeremy Stephen Gibbs | M | - |
University of Oxford
| 4 years |
| Robert Boisture | M | - |
University of Oxford
| 4 years |
| Rick Haythornthwaite | M | - |
University of Oxford
| 3 years |
| Vera Negri Zamagni | M | - |
University of Oxford
| 3 years |
| Abul Hasan Chowdhury | M | 73 |
University of Oxford
| 1 years |
| David Brayshaw | M | 70 |
University of Oxford
| 4 years |
| Imran Ahmed Khan Niazi | M | 71 |
University of Oxford
| 4 years |
| Ross Frederick Cranston | M | 75 |
University of Oxford
| 3 years |
| Robert David Campbell | M | 70 |
University of Oxford
| 1 years |
| Anthony White | M | 71 |
University of Oxford
| 3 years |
| Christopher Casey | M | 69 |
University of Oxford
| 4 years |
| George Borababy | M | - |
University of Oxford
| 4 years |
| Peter Norris | M | 69 |
University of Oxford
| 4 years |
| Patrick Daniel | M | 69 |
University of Oxford
| 4 years |
| John T. Bruer | M | - |
University of Oxford
| 4 years |
| Seong-Jun Yim | M | 75 |
University of Oxford
| 1 years |
| John Savill | M | - |
University of Oxford
| 4 years |
| Patrick Thomas | M | 67 |
University of Oxford
| 4 years |
| John Paul Paterson | M | - |
University of Oxford
| 4 years |
| Peter Mikkelsen | M | 71 |
University of Oxford
| 4 years |
| Kui Seng Tham | M | 66 |
University of Oxford
| 4 years |
| Lindsay Moffat Forbes | M | 71 |
University of Oxford
| 3 years |
| Andrew Joy | M | - |
University of Oxford
| 3 years |
| James E. MacLachlan | M | - |
University of Oxford
| 4 years |
| Harry Small | M | - |
University of Oxford
| 4 years |
| Jeremy Steven Philip Maynard | M | 70 |
University of Oxford
| 4 years |
| Gerard Evan | M | - |
University of Oxford
| 4 years |
| Charles Joseph Moore | M | - |
University of Oxford
| 2 years |
| Simon Acland | M | 66 |
University of Oxford
| 4 years |
| Michael Spencer | M | 69 |
University of Oxford
| 3 years |
| Jeremy Levin | M | 70 |
University of Oxford
| 3 years |
| Lynn Sharp Paine | M | 74 |
University of Oxford
| 3 years |
| Laurence R. O'Connell | M | 66 |
University of Oxford
| 4 years |
| Daniel J. Gennevois | M | 69 |
Roche Palo Alto LLC
Roche Palo Alto LLC Pharmaceuticals: MajorHealth Technology Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA. | 4 years |
| Andy Mills | M | 71 |
University of Oxford
| 4 years |
| Gary William Jarrett | M | - |
University of Oxford
| 1 years |
| Randall MacKey | M | 77 |
University of Oxford
| 3 years |
| Peter David Sadler | M | - |
University of Oxford
| 4 years |
| John Melotte | M | - |
University of Oxford
| 4 years |
| Adam Brunet | M | - |
University of Oxford
| 4 years |
| Henry Charles Anthony Hyde-Thomson | M | 70 |
University of Oxford
| 3 years |
| Antony Tyler | M | 69 |
University of Oxford
| 3 years |
| Robert Weinberg | M | 75 |
University of Oxford
| 3 years |
| John Campbell | M | 66 |
University of Oxford
| 4 years |
| Neil MacKilligin | M | - |
University of Oxford
| 4 years |
| Peter F. Leadlay | M | - |
University of Oxford
| 3 years |
| Peter Kiener | M | 72 |
University of Oxford
| 3 years |
| Thomas J. Dougherty | M | - |
University of Oxford
| 4 years |
| Colin Berkeley Moynihan | M | 67 |
University of Oxford
| 4 years |
| W. Edward Alastair Morrison | M | 66 |
University of Oxford
| 4 years |
| Alfred Putnam | M | - |
University of Oxford
| 4 years |
| Patrick J. S. Butler | M | 67 |
University of Oxford
| 4 years |
| Martin P. Rigby | M | - |
University of Oxford
| 3 years |
| Tim Parker | M | 68 |
University of Oxford
| 4 years |
| Lord Grimstone | M | - |
University of Oxford
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 72 | 72.00% |
| Canada | 17 | 17.00% |
| United States | 12 | 12.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ian John Massey
- Personal Network
